{
    "ticker": "WINT",
    "name": "Windtree Therapeutics, Inc.",
    "description": "Windtree Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies for the treatment of cardiovascular and pulmonary diseases. Founded in 1999, Windtree is dedicated to advancing its proprietary drug candidates to address significant unmet medical needs. The company's lead product, KL4, is a surfactant therapy designed for the treatment of conditions such as respiratory distress syndrome in infants and other pulmonary complications. Windtree's unique approach combines its expertise in surfactant biology with advanced drug delivery systems, aiming to improve patient outcomes and enhance the efficacy of existing treatments. The company is also exploring applications of its technologies in various therapeutic areas beyond pulmonary diseases, including cardiovascular health. Windtree Therapeutics is committed to scientific excellence and collaboration, engaging with healthcare professionals and researchers to drive innovation in drug development. Through its pipeline and strategic partnerships, Windtree strives to bring transformative therapies to market, ultimately improving the quality of life for patients suffering from debilitating conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Warrington, Pennsylvania, USA",
    "founded": "1999",
    "website": "https://www.windtreetx.com",
    "ceo": "Craig Fraser",
    "social_media": {
        "twitter": "https://twitter.com/WindtreeTX",
        "linkedin": "https://www.linkedin.com/company/windtree-therapeutics/"
    },
    "investor_relations": "https://www.windtreetx.com/investor-relations",
    "key_executives": [
        {
            "name": "Craig Fraser",
            "position": "CEO"
        },
        {
            "name": "Paul M. B. T. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pulmonary Therapies",
            "products": [
                "KL4"
            ]
        }
    ],
    "seo": {
        "meta_title": "Windtree Therapeutics, Inc. | Innovative Pulmonary and Cardiovascular Therapies",
        "meta_description": "Explore Windtree Therapeutics, Inc., a biotechnology company dedicated to developing innovative therapies for cardiovascular and pulmonary diseases.",
        "keywords": [
            "Windtree Therapeutics",
            "Biotechnology",
            "Cardiovascular Therapies",
            "Pulmonary Diseases",
            "KL4"
        ]
    },
    "faq": [
        {
            "question": "What is Windtree Therapeutics known for?",
            "answer": "Windtree Therapeutics is known for developing innovative therapies for pulmonary and cardiovascular diseases, particularly its lead product KL4."
        },
        {
            "question": "Who is the CEO of Windtree Therapeutics?",
            "answer": "Craig Fraser is the CEO of Windtree Therapeutics, Inc."
        },
        {
            "question": "Where is Windtree Therapeutics headquartered?",
            "answer": "Windtree Therapeutics is headquartered in Warrington, Pennsylvania, USA."
        },
        {
            "question": "What are Windtree's main products?",
            "answer": "Windtree's main product is KL4, a surfactant therapy for respiratory conditions."
        },
        {
            "question": "When was Windtree Therapeutics founded?",
            "answer": "Windtree Therapeutics was founded in 1999."
        }
    ],
    "competitors": [
        "VRTX",
        "MNKD",
        "PTCT"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "BIIB"
    ]
}